ALSO NOTED: U.K. calls for halt to HIV study; Cadence to raise $49.3M; and much more...

> The U.K.'s Medical Research Council has advised Indevus Pharmaceuticals to close the high-dose arm of it's Phase III HIV study. Release

> Cadence Pharmaceuticals is raising $49.3 million in a registered direct common stock offering. Release

> The heparin pile-on has begun--but this time, the FDA is at the bottom, not the drugmaker. Report

> Well, we didn't have to watch Alex Gorsky for long. According to the Wall Street Journal, when Novartis said that the U.S. pharma CEO was leaving, they left out the part about his returning to alma mater Johnson & Johnson. Report

> The FDA has approved a label change adding depression as a possible side effect of the cholesterol meds Vytorin and Zetia. Report

> Sanofi Pasteur has submitted the first vaccine delivered by an intradermal microinjection system for European approval. Report

> Despite spending a dramatically higher amount than before on treatments for spinal pain, Americans aren't getting great results, according to a new study. Report

> FierceHealthcare asks: Would a new agency curb pharma marketing misdeeds? Editorial

And Finally... Natural purple pigments found in fruits, vegetables and berries may help prevent obesity. Release

Suggested Articles

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.